non-SMC condensin I complex subunit G pseudogene 1Genealiases: []
Q-omics provides the consensus-scored NCAPGP1 profile across patient tissues and cancer cell-line models. NCAPGP1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NCAPGP1 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, NCAPGP1 RNA expression shows 12,823 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, COAD, and ESCA as cancer lineages where NCAPGP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NCAPGP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NCAPGP1 survival associations across molecular data types. NCAPGP1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NCAPGP1 RNA expression–survival associations across cancer types. High NCAPGP1 expression shows unfavorable associations in KIRC, COAD, KIRP, SARC, LGG and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NCAPGP1 RNA expression.
This table summarizes NCAPGP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for NCAPGP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NCAPGP1 shows lower tumor expression in LUSC and higher tumor expression in COAD, STAD, ESCA, KICH and UCEC. The COAD box plot shows higher NCAPGP1 RNA expression in tumor versus normal tissue (log2 FC = +0.198, t-test p < 0.001).
This table shows molecular features associated with NCAPGP1 in patient tissues and cancer cell lines. In patient samples, NCAPGP1 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
